These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

77 related articles for article (PubMed ID: 21316232)

  • 1. 4-aminopyrimidine-5-carbaldehyde oximes as potent VEGFR-2 inhibitors. Part II.
    Huang S; Li R; LaMontagne KR; Greenberger LM; Connolly PJ
    Bioorg Med Chem Lett; 2011 Mar; 21(6):1815-8. PubMed ID: 21316232
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Synthesis and biological study of 4-aminopyrimidine-5-carboxaldehyde oximes as antiproliferative VEGFR-2 inhibitors.
    Huang S; Li R; Connolly PJ; Xu G; Gaul MD; Emanuel SL; Lamontagne KR; Greenberger LM
    Bioorg Med Chem Lett; 2006 Dec; 16(23):6063-6. PubMed ID: 16979339
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Synthesis and biological study of 2-amino-4-aryl-5-chloropyrimidine analogues as inhibitors of VEGFR-2 and cyclin dependent kinase 1 (CDK1).
    Huang S; Li R; Connolly PJ; Emanuel S; Fuentes-Pesquera A; Adams M; Gruninger RH; Seraj J; Middleton SA; Davis JM; Moffat DF
    Bioorg Med Chem Lett; 2007 Apr; 17(8):2179-83. PubMed ID: 17317182
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A highly selective, orally bioavailable, vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor has potent activity in vitro and in vivo.
    LaMontagne KR; Butler J; Borowski VB; Fuentes-Pesquera AR; Blevitt JM; Huang S; Li R; Connolly PJ; Greenberger LM
    Angiogenesis; 2009; 12(3):287-96. PubMed ID: 19544081
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Design, synthesis and biological evaluation of 4-aminopyrimidine-5-cabaldehyde oximes as dual inhibitors of c-Met and VEGFR-2.
    Qiang H; Gu W; Huang D; Shi W; Qiu Q; Dai Y; Huang W; Qian H
    Bioorg Med Chem; 2016 Aug; 24(16):3353-8. PubMed ID: 27068889
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Design and synthesis of dihydroindazolo[5,4-a]pyrrolo[3,4-c]carbazole oximes as potent dual inhibitors of TIE-2 and VEGF-R2 receptor tyrosine kinases.
    Dandu R; Zulli AL; Bacon ER; Underiner T; Robinson C; Chang H; Miknyoczki S; Grobelny J; Ruggeri BA; Yang S; Albom MS; Angeles TS; Aimone LD; Hudkins RL
    Bioorg Med Chem Lett; 2008 Mar; 18(6):1916-21. PubMed ID: 18308565
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Discovery of novel 4-amino-6-arylaminopyrimidine-5-carbaldehyde oximes as dual inhibitors of EGFR and ErbB-2 protein tyrosine kinases.
    Xu G; Searle LL; Hughes TV; Beck AK; Connolly PJ; Abad MC; Neeper MP; Struble GT; Springer BA; Emanuel SL; Gruninger RH; Pandey N; Adams M; Moreno-Mazza S; Fuentes-Pesquera AR; Middleton SA; Greenberger LM
    Bioorg Med Chem Lett; 2008 Jun; 18(12):3495-9. PubMed ID: 18508264
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Discovery of novel VEGFR-2 inhibitors. Part II: biphenyl urea incorporated with salicylaldoxime.
    Gao H; Su P; Shi Y; Shen X; Zhang Y; Dong J; Zhang J
    Eur J Med Chem; 2015 Jan; 90():232-40. PubMed ID: 25461323
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Arylphthalazines. Part 2: 1-(Isoquinolin-5-yl)-4-arylamino phthalazines as potent inhibitors of VEGF receptors I and II.
    Duncton MA; Piatnitski EL; Katoch-Rouse R; Smith LM; Kiselyov AS; Milligan DL; Balagtas C; Wong WC; Kawakami J; Doody JF
    Bioorg Med Chem Lett; 2006 Mar; 16(6):1579-81. PubMed ID: 16386418
    [TBL] [Abstract][Full Text] [Related]  

  • 10. 1,2,3-Thiadiazole substituted pyrazolones as potent KDR/VEGFR-2 kinase inhibitors.
    Tripathy R; Ghose A; Singh J; Bacon ER; Angeles TS; Yang SX; Albom MS; Aimone LD; Herman JL; Mallamo JP
    Bioorg Med Chem Lett; 2007 Mar; 17(6):1793-8. PubMed ID: 17239587
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hetaryl imidazoles: a novel dual inhibitors of VEGF receptors I and II.
    Kiselyov AS; Semenova M; Semenov VV; Piatnitski E; Ouyang S
    Bioorg Med Chem Lett; 2006 Mar; 16(5):1440-4. PubMed ID: 16321531
    [TBL] [Abstract][Full Text] [Related]  

  • 12. 4-Amino-6-piperazin-1-yl-pyrimidine-5-carbaldehyde oximes as potent FLT-3 inhibitors.
    Gaul MD; Xu G; Kirkpatrick J; Ott H; Baumann CA
    Bioorg Med Chem Lett; 2007 Sep; 17(17):4861-5. PubMed ID: 17611106
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacological characterization of CP-547,632, a novel vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor for cancer therapy.
    Beebe JS; Jani JP; Knauth E; Goodwin P; Higdon C; Rossi AM; Emerson E; Finkelstein M; Floyd E; Harriman S; Atherton J; Hillerman S; Soderstrom C; Kou K; Gant T; Noe MC; Foster B; Rastinejad F; Marx MA; Schaeffer T; Whalen PM; Roberts WG
    Cancer Res; 2003 Nov; 63(21):7301-9. PubMed ID: 14612527
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Arylphthalazines: identification of a new phthalazine chemotype as inhibitors of VEGFR kinase.
    Piatnitski EL; Duncton MA; Kiselyov AS; Katoch-Rouse R; Sherman D; Milligan DL; Balagtas C; Wong WC; Kawakami J; Doody JF
    Bioorg Med Chem Lett; 2005 Nov; 15(21):4696-8. PubMed ID: 16143524
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Novel potent orally active selective VEGFR-2 tyrosine kinase inhibitors: synthesis, structure-activity relationships, and antitumor activities of N-phenyl-N'-{4-(4-quinolyloxy)phenyl}ureas.
    Kubo K; Shimizu T; Ohyama S; Murooka H; Iwai A; Nakamura K; Hasegawa K; Kobayashi Y; Takahashi N; Takahashi K; Kato S; Izawa T; Isoe T
    J Med Chem; 2005 Mar; 48(5):1359-66. PubMed ID: 15743179
    [TBL] [Abstract][Full Text] [Related]  

  • 16. SAR of a novel 'Anthranilamide Like' series of VEGFR-2, multi protein kinase inhibitors for the treatment of cancer.
    Wickens P; Kluender H; Dixon J; Brennan C; Achebe F; Bacchiocchi A; Bankston D; Bierer D; Brands M; Braun D; Brown MS; Chuang CY; Dumas J; Enyedy I; Hofilena G; Hong Z; Housley T; Jones B; Khire U; Kreiman C; Kumarasinghe E; Lowinger T; Ott-Morgan R; Perkins L; Phillips B; Schoenleber R; Scott WJ; Sheeler R; Redman A; Sun X; Taylor I; Wang L; Wilhelm S; Zhang X; Zhang M; Sullivan E; Carter C; Miglarese M; Levy J
    Bioorg Med Chem Lett; 2007 Aug; 17(15):4378-81. PubMed ID: 17574417
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Synthesis, SAR, and Evaluation of 4-[2,4-Difluoro-5-(cyclopropylcarbamoyl)phenylamino]pyrrolo[2,1-f][1,2,4]triazine-based VEGFR-2 kinase inhibitors.
    Cai ZW; Wei D; Borzilleri RM; Qian L; Kamath A; Mortillo S; Wautlet B; Henley BJ; Jeyaseelan R; Tokarski J; Hunt JT; Bhide RS; Fargnoli J; Lombardo LJ
    Bioorg Med Chem Lett; 2008 Feb; 18(4):1354-8. PubMed ID: 18221875
    [TBL] [Abstract][Full Text] [Related]  

  • 18. 4-(Azolylphenyl)-phthalazin-1-amines: Novel inhibitors of VEGF receptors I and II.
    Kiselyov AS; Semenov VV; Milligan D
    Chem Biol Drug Des; 2006 Dec; 68(6):308-13. PubMed ID: 17177892
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Discovery of novel benzimidazoles as potent inhibitors of TIE-2 and VEGFR-2 tyrosine kinase receptors.
    Hasegawa M; Nishigaki N; Washio Y; Kano K; Harris PA; Sato H; Mori I; West RI; Shibahara M; Toyoda H; Wang L; Nolte RT; Veal JM; Cheung M
    J Med Chem; 2007 Sep; 50(18):4453-70. PubMed ID: 17676829
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Synthesis and structure-activity relationships of pyrazine-pyridine biheteroaryls as novel, potent, and selective vascular endothelial growth factor receptor-2 inhibitors.
    Kuo GH; Prouty C; Wang A; Emanuel S; Deangelis A; Zhang Y; Song F; Beall L; Connolly PJ; Karnachi P; Chen X; Gruninger RH; Sechler J; Fuentes-Pesquera A; Middleton SA; Jolliffe L; Murray WV
    J Med Chem; 2005 Jul; 48(15):4892-909. PubMed ID: 16033269
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.